TFS Capital LLC bought a new stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 17,125 shares of the company’s stock, valued at approximately $356,000. TFS Capital LLC owned 0.08% of Corvus Pharmaceuticals as of its most recent filing with the SEC.
Other hedge funds have also added to or reduced their stakes in the company. TD Asset Management Inc. boosted its stake in shares of Corvus Pharmaceuticals by 8.1% in the first quarter. TD Asset Management Inc. now owns 24,049 shares of the company’s stock worth $499,000 after buying an additional 1,805 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Corvus Pharmaceuticals by 62.4% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 15,350 shares of the company’s stock worth $220,000 after buying an additional 5,900 shares during the last quarter. Essex Investment Management Co. LLC boosted its stake in Corvus Pharmaceuticals by 46.7% in the first quarter. Essex Investment Management Co. LLC now owns 31,225 shares of the company’s stock valued at $649,000 after buying an additional 9,933 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Corvus Pharmaceuticals during the first quarter valued at about $331,000. Finally, Russell Investments Group Ltd. purchased a new stake in Corvus Pharmaceuticals during the fourth quarter valued at about $402,000. Hedge funds and other institutional investors own 82.85% of the company’s stock.
Corvus Pharmaceuticals, Inc. (CRVS) traded up 1.82% during midday trading on Monday, reaching $11.20. The company had a trading volume of 129,922 shares. The company’s 50-day moving average is $10.44 and its 200 day moving average is $13.66. The company’s market cap is $234.46 million. Corvus Pharmaceuticals, Inc. has a 52-week low of $8.27 and a 52-week high of $22.14.
Several equities research analysts have issued reports on CRVS shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $25.00 price target on shares of Corvus Pharmaceuticals in a research note on Wednesday, April 5th. Cowen and Company reissued a “buy” rating on shares of Corvus Pharmaceuticals in a research report on Tuesday, May 2nd. Zacks Investment Research downgraded shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 21st. Finally, Credit Suisse Group dropped their price target on shares of Corvus Pharmaceuticals from $26.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, April 6th.
In related news, insider Richard A. Md Miller acquired 25,000 shares of the company’s stock in a transaction on Tuesday, June 13th. The stock was purchased at an average cost of $9.88 per share, with a total value of $247,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.